1,748
Views
1
CrossRef citations to date
0
Altmetric
Genetic Disease

Assessment of face validity of a disease model of nonsense mutation Duchenne muscular dystrophy: a multi-national Delphi panel study

ORCID Icon, , , , , , , , , , & show all
Pages 808-816 | Received 15 Apr 2022, Accepted 31 May 2022, Published online: 14 Jun 2022

Figures & data

Figure 1. Panelists’ responses to Health Utilities Index-question 7 (emotion). Note: Ataluren in addition to best supportive care (ATA). Best supportive care (BSC). The HUI item-specific levels range from ‘a’ (indicating no/minimal negative impact on health status and a low/minimal disease burden) to ‘e’ (indicating a very high degree of impairment/compromise and a high/maximum disease burden).

Figure 1. Panelists’ responses to Health Utilities Index-question 7 (emotion). Note: Ataluren in addition to best supportive care (ATA). Best supportive care (BSC). The HUI item-specific levels range from ‘a’ (indicating no/minimal negative impact on health status and a low/minimal disease burden) to ‘e’ (indicating a very high degree of impairment/compromise and a high/maximum disease burden).

Figure 2. Panelists’ responses to Health Utilities Index-question 8 (pain and discomfort). Note: Ataluren in addition to best supportive care (ATA). Best supportive care (BSC). The HUI item-specific levels range from ‘a’ (indicating no/minimal negative impact on health status and a low/minimal disease burden) to ‘e’ (indicating a very high degree of impairment/compromise and a high/maximum disease burden).

Figure 2. Panelists’ responses to Health Utilities Index-question 8 (pain and discomfort). Note: Ataluren in addition to best supportive care (ATA). Best supportive care (BSC). The HUI item-specific levels range from ‘a’ (indicating no/minimal negative impact on health status and a low/minimal disease burden) to ‘e’ (indicating a very high degree of impairment/compromise and a high/maximum disease burden).

Figure 3. Panelists’ responses to Health Utilities Index-question 9 (ambulation). Note: The HUI item-specific levels range from ‘a’ (indicating no/minimal negative impact on health status and a low/minimal disease burden) to ‘f’ (indicating a very high degree of impairment/compromise and a high/maximum disease burden). Ataluren was assumed to be administered from a mean patient age of 5 years and continue up until and beyond loss of independent ambulation. Mobility in disease stages (2), (3), and (4) was ‘f’ (‘Unable to walk at all’). Ataluren in addition to best supportive care (ATA). Best supportive care (BSC).

Figure 3. Panelists’ responses to Health Utilities Index-question 9 (ambulation). Note: The HUI item-specific levels range from ‘a’ (indicating no/minimal negative impact on health status and a low/minimal disease burden) to ‘f’ (indicating a very high degree of impairment/compromise and a high/maximum disease burden). Ataluren was assumed to be administered from a mean patient age of 5 years and continue up until and beyond loss of independent ambulation. Mobility in disease stages (2), (3), and (4) was ‘f’ (‘Unable to walk at all’). Ataluren in addition to best supportive care (ATA). Best supportive care (BSC).

Figure 4. Panelists’ responses to Health Utilities Index-question 10 (dexterity). Note: The HUI item-specific levels range from ‘a’ (indicating no/minimal negative impact on health status and a low/minimal disease burden) to ‘f’ (indicating a very high degree of impairment/compromise and a high/maximum disease burden). Ataluren was assumed to be administered from a mean patient age of 5 years and continue up until and beyond loss of independent ambulation. Ataluren in addition to best supportive care (ATA). Best supportive care (BSC).

Figure 4. Panelists’ responses to Health Utilities Index-question 10 (dexterity). Note: The HUI item-specific levels range from ‘a’ (indicating no/minimal negative impact on health status and a low/minimal disease burden) to ‘f’ (indicating a very high degree of impairment/compromise and a high/maximum disease burden). Ataluren was assumed to be administered from a mean patient age of 5 years and continue up until and beyond loss of independent ambulation. Ataluren in addition to best supportive care (ATA). Best supportive care (BSC).
Supplemental material

Supplemental Material

Download MS Word (18.7 KB)

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.